2.41  1.13 (88.28%)		06-09 16:00
Open: 2.52 High: 6.55 Volume: 103,570,682		Pre. Close: 1.28 Low: 2.23 Market Cap: 9(M)

Short term
Mid term
Targets	6-month :	5.27	1-year :	7.65
Resists	First :	4.51	Second :	6.55
Pivot price	1.88
Supports	First :	1.23	Second :	1.02
MAs	MA(5) :	1.7	MA(20) :	1.93
	MA(100) :	3.5	MA(250) :	0
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	9.3	D(3) :	10
RSI	RSI(14): 57.2
52-week	High :	8.35	Low :	1.23

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RGNT ] has closed below upper band by 6.6%. Bollinger Bands are 8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.55 - 6.59	6.59 - 6.63
Low:	2.2 - 2.21	2.21 - 2.23
Close:	2.42 - 2.45	2.45 - 2.47

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

Tue, 09 Jun 2026
RGNT Stock Rockets On High-Volume Breakout Volatility - StocksToTrade

Tue, 09 Jun 2026
RGNT Stock Slides After Volatile Spike Draws Trader Focus - timothysykes.com

Mon, 08 Jun 2026
Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC - Yahoo Finance

Mon, 08 Jun 2026
Regentis Biomaterials Ltd. Ordinary Shares (NYSE:RGNT) Stock Quote - FinancialContent

Mon, 08 Jun 2026
Regentis Biomaterials (NASDAQ: RGNT) plans European surgeon training as GelrinC launch nears - Stock Titan

Tue, 02 Jun 2026
Number of shareholders of Regentis Biomaterials Ltd. – AMEX:RGNT - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.